Progress in the development of new therapies for herpesvirus infections
- 31 December 2011
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Virology
- Vol. 1 (6), 548-554
- https://doi.org/10.1016/j.coviro.2011.10.015
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infectionAntiviral Research, 2011
- Cyclopropavir Inhibits the Normal Function of the Human Cytomegalovirus UL97 KinaseAntimicrobial Agents and Chemotherapy, 2011
- CMX001 Potentiates the Efficacy of Acyclovir in Herpes Simplex Virus InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and ManagementAntimicrobial Agents and Chemotherapy, 2011
- Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir SusceptibilityAntimicrobial Agents and Chemotherapy, 2011
- Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution StudiesThe Journal of Infectious Diseases, 2010
- Stereoselective Phosphorylation of Cyclopropavir by pUL97 and Competitive Inhibition by MaribavirAntimicrobial Agents and Chemotherapy, 2010
- In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246Antimicrobial Agents and Chemotherapy, 2010
- Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under MaribavirAntimicrobial Agents and Chemotherapy, 2009
- Maribavir Antagonizes the Antiviral Action of Ganciclovir on Human CytomegalovirusAntimicrobial Agents and Chemotherapy, 2006